Evidence map›Paper›PMID 39520524›Full record

Trial reportDysphagia2025

Oral Transport, Penetration, and Aspiration in PD: Insights from a RCT on STN + SNr Stimulation.

Idil Cebi, Lisa Helene Graf, Marion Schütt, Mohammad Hormozi, Philipp Klocke, Moritz Löffler, Marlieke Schneider, Tobias Warnecke, Alireza Gharabaghi, Daniel Weiss

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Dysphagia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Idil CebiCentre of Neurology and Department of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Hoppe- Seyler- Str. 3, 72076, Tuebingen, Germany.
Lisa Helene GrafCentre of Neurology and Department of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Hoppe- Seyler- Str. 3, 72076, Tuebingen, Germany.
Marion SchüttInstitute for Clinical Epidemiology and Applied Biometry at the University Hospital Tübingen, Tuebingen, Germany.
Mohammad HormoziCentre of Neurology and Department of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Hoppe- Seyler- Str. 3, 72076, Tuebingen, Germany.
Philipp KlockeCentre of Neurology and Department of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Hoppe- Seyler- Str. 3, 72076, Tuebingen, Germany.
Moritz LöfflerCentre of Neurology and Department of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Hoppe- Seyler- Str. 3, 72076, Tuebingen, Germany.
Marlieke SchneiderCentre of Neurology and Department of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Hoppe- Seyler- Str. 3, 72076, Tuebingen, Germany.
Tobias WarneckeDepartment of Neurology and Neurorehabilitation, Klinikum Osnabrueck - Academic Teaching Hospital of the WWU, Muenster, Germany.
Alireza GharabaghiInstitute for Neuromodulation and Neurotechnology, University Hospital and University of Tübingen, 72076, Tübingen, Germany.
Daniel WeissCentre of Neurology and Department of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research (HIH), University of Tübingen, Hoppe- Seyler- Str. 3, 72076, Tuebingen, Germany. daniel.weiss@uni-tuebingen.de.ORCID http://orcid.org/0000-0003-0447-7132

Funding

Michael J. Fox Foundation for Parkinson's Research Michael J. Fox Foundation for Parkinson's Research
6 · The paper itself

Abstract

Dysphagia is frequent and detrimental in advanced Parkinson's disease (PD) and does not respond to standard treatments. Experimental models suggested that pathological overactivity of the substantia nigra pars reticulata (SNr) may hinder oral contributions to swallowing. Here, we hypothesized that the combined stimulation of subthalamic nucleus (STN) and SNr improves measures of dysphagia after eight weeks of active treatment. We enrolled 20 PD patients with dysphagia and deep brain stimulation (DBS). Patients were assessed in 'medication on' and 'STN' stimulation at baseline (V1) and then were randomized 1:1 to 'STN' or 'STN + SNr' stimulation. In addition, patients of both groups received swallowing therapy as a standard of care. The primary endpoint was the change in Penetration-Aspiration Scale (PAS) at eight-week follow-up (V2) with respect to the baseline (V1) under the hypothesis, that 'STN + SNr' was superior to 'STN'. We obtained further secondary endpoints on oral preparation, transport, pharyngeal phase, penetration, and aspiration. PAS change from V1 to V2 was not significantly different between groups (p = 0.221). When considering all patients for secondary analyses, we found that the entire study cohort showed better PAS scores at V2 compared to V1 irrespective from DBS treatment allocation (p = 0.0156). Both STN and STN + SNr treatments were safe. 'STN + SNr' stimulation was not superior compared to standard 'STN' stimulation both on PAS and the secondary endpoints. We found that the entire study cohort improved dysphagia after eight weeks, which presumably mirrors the effect of continued swallowing therapy and the increased patient attention on swallowing.

Indexed as

Deep Brain StimulationDeglutition DisordersParkinson DiseaseRespiratory AspirationSubthalamic NucleusAgedDeglutitionFemaleHumansMaleMiddle AgedTreatment OutcomeDeep brain stimulationDysphagiaParkinson’s diseasesubstantia nigraSubthalamic nucleus

Identifiers

PMID39520524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.